Observational study on efficacy, safety, and drug survival of anakinra in rheumatoid arthritis patients in clinical practice

Annals of the Rheumatic Diseases

Volumn 65, Issue 6, 2006, Pages 760-762

  Den Broeder, A A ^a,b   De Jong, E ^b   Franssen, M J A M ^b   Jeurissen, M E C ^b   Flendrie, M ^a   Van Den Hoogen, F H J ^a,b  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b SINT MAARTENSKLINIEK   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; CORTICOSTEROID; DISEASE MODIFYING ANTIRHEUMATIC DRUG; METHOTREXATE; PREDNISONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT;

ADULT; ARTHRALGIA; ARTHROPATHY; ARTICLE; BASAL CELL CARCINOMA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DISEASE EXACERBATION; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; INFECTION; INJECTION SITE REACTION; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; PROGNOSIS; PRURITUS; RECTUM CARCINOMA; RHEUMATOID ARTHRITIS; SCORING SYSTEM; SURVIVAL; TREATMENT WITHDRAWAL;

AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; EPIDEMIOLOGIC METHODS; FEMALE; HUMANS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; MALE; MIDDLE AGED; RECEPTORS, INTERLEUKIN-1; SIALOGLYCOPROTEINS; THROMBOCYTOPENIA;

EID: 33744495746     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2004.033662     Document Type: Article

References (18)

1. Campion GV, Lebsack ME, Lookabaugh J, Gordon G, Catalano M. Dose-range and dose-frequency study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis. Arthritis Rheum 1996;39:1092-101.
2. Nuki G, Breshnihan B, Moraye BB, McCabe D. Long-term safety and maintenance of clinical improvement following treatment with anakinra (recombinant human interleukin-1 receptor antagonist) in patients with rheumatoid arthritis. Arthritis Rheum 2002;46:2838-46.
3. Fleischmann RM, Schechtsman J, Bennett R, Handel ML, Burmester GR, Tesser J, et al. Anakinra, a recombinant human interleukin-1 antagonist (r-metHuIL-1 ra), in patients with rheumatoid arthritis. Arthritis Rheum 2003;48:927-34.
4. Schiff MH, DiVittorio G, Tesser J, Fleischmann R, Schechtman J, Hartman S, et al. The safety of anakinra in high-risk patients with active rheumatoid arthritis: six-month observations of patients with comorbid conditions. Arthritis Rheum 2004;50:1752-60.
5. Cohen S, Hurd E, Cush J, Schiff M, Weinblatt ME, Moreland LW, et al. Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002;46:614-24.
6. Cohen SB, Moreland LW, Cush JJ, Greenwald MW, Block S, Shergy WJ, et al. A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate. Ann Rheum Dis 2004;63:1062-8.
7. Gebovese MC, Cohen SB, Moreland L, Lium D, Robbins S, Newmark R, et al. Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate. Arthritis Rheum 2004;50:1412-19.
8. Burls A, Jobanputra P. The trials of anakinra. Lancet 2004;364:827-8.
9. van Gestel AM, Prevoo MLL, van 't Hof MA, van Rijswijk MH, van de Putte LBA, van Riel PLCM. Development and validation of the European league against rheumatism response criteria for rheumatoid arthritis. Arthritis Rheum 1996;39:34-40.
10. Cancer Therapy Evaluation Program. Revised 23 March 1998. Common toxicity criteria, version 2.0. DCTD, NCI, NIH, DHHS, March, 1998.
11. Eriksson C, Engstrand S, Sundqvist KG, Rantapaa-Dahlqvist S. Autoantibody formation in patients with rheumatoid arthritis treated with anti-TNF-alpha therapy. Ann Rheum Dis 2005;64:403-7.
12. Wolbink GJ, Voskuyl A, Lems W, de Groot E, Nurmohamed MT, Tak PP, et al. Relationship between serum trough infliximab levels, pretreatment C reactive protein levels, and clinical response to infliximab treatment in patients with rheumatoid arthritis. Ann Rheum Dis 2005;64:704-7.
13. Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, Macfarlane JD. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998;41:1552-63.
14. Buch MH, Bingham SJ, Yohei S, McGonagle D, Bejarano V, White J, et al. Lack of response to anakinra in rheumatoid arthritis following failure of tumor necrosis factor α (alfa) blockade. Arthritis Rheum, 2004;50:725-8.
15. Langer HE, Missler-Karger B. Kineret: efficacy and safety in daily clinical practice: an interim analysis of the Kineret response assessment initiative (kreative) protocol. Int J Clin Pharmacol Res 2003;23:119-28.
16. Nancy J Olsen, C Michael Stein. New Drugs for Rheumatoid Arthritis. N Engl J Med 2000;350:2167-79.
17. Flendrie M, Creemers MC, Welsing PM, den Broeder AA, van Riel PL. Drug-survival during treatment with tumour necrosis factor blocking agents in rheumatoid arthritis. Ann Rheum Dis 2003;62(suppl 2):ii30-3.
18. Geborek P, Crnkic M, Petersson IF, Saxne T. South Swedish Arthritis Treatment Group. Etanercept, infliximab, and leflunomide in established rheumatoid arthritis: clinical experience using a structured follow up program in southern Sweden. Ann Rheum Dis 2002;61:793-8.